We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+13.18%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$25B
AUM Growth
+$2.35B
Cap. Flow
+$638M
Cap. Flow %
2.55%
Top 10 Hldgs %
85.68%
Holding
126
New
11
Increased
17
Reduced
63
Closed
6

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$358M
2
PRLD icon
Prelude Therapeutics
PRLD
+$286M
3
KYMR icon
Kymera Therapeutics
KYMR
+$59.8M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$55.5M
5
NRIX icon
Nurix Therapeutics
NRIX
+$45.1M

Top Sells

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$94.5M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$26.6M
3
TCDA
Tricida, Inc. Common Stock
TCDA
+$21.6M
4
INSM icon
Insmed
INSM
+$21.6M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$16.5M

Sector Composition

Rank Sector Weight
1 Healthcare 97.35%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AUTL
76
Autolus Therapeutics
AUTL
$378M
$5.37M 0.02%
461,324
-24,300
-5% -$352K
RETA
77
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$5.18M 0.02%
53,183
-2,800
-5% -$350K
REPL icon
78
Replimune Group
REPL
$424M
$4.76M 0.02%
206,586
+201,445
+3,918% +$4.59M
CRNX icon
79
Crinetics Pharmaceuticals
CRNX
$8.88B
$4.74M 0.02%
302,320
-15,537
-5% -$238K
IFRX icon
80
InflaRx
IFRX
$246M
$4.29M 0.02%
1,007,559
-50,996
-5% -$235K
ITOS
81
DELISTED
iTeos Therapeutics
ITOS
$4.13M 0.02%
+167,562
New +$4.51M
AKRO
82
DELISTED
Akero Therapeutics
AKRO
$4.06M 0.02%
+131,788
New +$4.61M
LEGN icon
83
Legend Biotech
LEGN
$3.65B
$3.96M 0.02%
128,200
-6,800
-5% -$229K
DNLI icon
84
Denali Therapeutics
DNLI
$3.78B
$3.56M 0.01%
99,400
-5,500
-5% -$166K
PASG icon
85
Passage Bio
PASG
$14.2M
$3.42M 0.01%
13,053
-697
-5% -$240K
OVID icon
86
Ovid Therapeutics
OVID
$424M
$3.39M 0.01%
590,761
+132,508
+29% +$887K
TARA icon
87
Protara Therapeutics
TARA
$213M
$3.36M 0.01%
199,671
– –
CHMA
88
DELISTED
Chiasma, Inc. Common Stock
CHMA
$3.19M 0.01%
742,133
-204,568
-22% -$979K
INZY
89
DELISTED
Inozyme Pharma
INZY
$3.12M 0.01%
+118,500
New +$2.94M
XLRN
90
DELISTED
Acceleron Pharma
XLRN
$2.88M 0.01%
25,640
-1,360
-5% -$135K
ALEC icon
91
Alector
ALEC
$170M
$2.8M 0.01%
265,600
-14,400
-5% -$233K
KZR
92
DELISTED
Kezar Life Sciences
KZR
$2.78M 0.01%
57,496
-2,504
-4% -$120K
CNST
93
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$2.7M 0.01%
133,333
– –
GMDA
94
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$2.63M 0.01%
633,324
-33,342
-5% -$142K
TCRR
95
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$2.49M 0.01%
+122,532
New +$2.15M
NTLA icon
96
Intellia Therapeutics
NTLA
$1.5B
$2.43M 0.01%
122,238
-6,300
-5% -$131K
VKTX icon
97
Viking Therapeutics
VKTX
$3.86B
$2.35M 0.01%
404,200
-20,800
-5% -$143K
DRNA
98
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$2.04M 0.01%
113,135
-6,200
-5% -$128K
RCUS icon
99
Arcus Biosciences
RCUS
$3.3B
$1.98M 0.01%
115,425
-6,109
-5% -$136K
NGM
100
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$1.88M 0.01%
118,100
-6,300
-5% -$115K
1 2 3
4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2020 Portfolio in Review

As of Q3 2020, Baker Bros. Advisors held 126 positions worth $25B, up 10% from $22.7B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Baker Bros. Advisors's Q3 2020 filing shows 11 new, 17 increased, 63 reduced and 6 closed positions. Its largest new stake was Prelude Therapeutics: 10,118,636 shares worth $305M. The largest sale was Principia Biopharma Inc. Common Stock, an estimated $94.5M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q3 2020 buy was Prelude Therapeutics: 10,118,636 shares worth $305M.
  • Baker Bros. Advisors added most to BeOne Medicines Ltd in Q3 2020, an estimated $358M increase.
  • Baker Bros. Advisors's biggest Q3 2020 reduction was Neurocrine Biosciences, cutting an estimated $26.6M.
  • Baker Bros. Advisors fully exited Principia Biopharma Inc. Common Stock in Q3 2020, selling an estimated $94.5M.
  • Baker Bros. Advisors's ten largest holdings make up 86% of its $25B portfolio in Q3 2020.
  • Baker Bros. Advisors opened 11 new positions and closed 6 in Q3 2020.
  • Baker Bros. Advisors's portfolio value rose 10% quarter-over-quarter to $25B.

Based on Baker Bros. Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.